Fig 4.

Summary of prognosis impact of somatic mutations evaluated in retrospective studies or clinical trials in chronic lymphocytic leukemia (CLL). The medians of time to first treatment (TTFT), overall survival (OS), and progression-free survival (PFS) in subgroups of patients with CLL with mutations are indicated in months and compared with subgroups of patients with wild type (in parentheses). When medians were not available in studies, the value of the hazard ratio in multivariable analyses is reported in square brackets. The UK Leukaemia Research Fund (LRF) CLL4 trial⁸³ compared median months for the ATM biallelic inactivation subgroup with ATM wild type and ATM mutation subgroup. Data from the German CLL Study Group (GCLLSG) CLL3X trial⁸⁴ were inferred from Kaplan-Meier curves. ERIC, European Research Initiative on CLL; FILO, French Intergroup on CLL; IPI, International Prognostic Index; MLL, Munich Leukemia Laboratory; NA, not available; NCRN, National Cancer Research Network; NR, not reached; ORR, overall response rate; R/R, relapsed/refractory; SCALE, Scandinavian Lymphoma Etiology. *5-year OS rate (%). †10-year rate (%).